To identify subgroups of HER2-positive breast cancer patients with liver metastases (n=29) who may derive greater benefit from pyrotinib treatment, a subgroup analysis was performed based on HR status (ER, PR, or combined), Ki67 expression levels, and lymph node metastasis status. Here, ESR1 is linked to breast cancer.